SCM
RVNC

Stevens Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Stevens Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,087
Closed -$242K – 1154
2015
Q4 		$242K Buy
+7,087
New +$246K 0.01% 748

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stevens Capital Management's RVNC Position: Q1 2016 in Review

Stevens Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2016, closing a stake of 7,087 shares — an estimated $242K sold.

Stevens Capital Management first reported a position in RVNC in Q4 2015 and held it in 1 quarter. The position peaked at $242K in Q4 2015. 86 funds tracked by Wall St. Rank hold RVNC as of Q1 2016.

  • Stevens Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Stevens Capital Management sold 7,087 Revance Therapeutics, Inc. shares in Q1 2016, an estimated $242K.
  • Stevens Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Stevens Capital Management's Revance Therapeutics, Inc. position peaked at $242K in Q4 2015.
  • 86 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2016.

Based on Stevens Capital Management's 13F filing for Q1 2016, filed 13 May 2016.